Pharmaceutically active secondary metabolites of microorganisms

被引:295
作者
Demain, AL [1 ]
机构
[1] MIT, Dept Biol, Fermentat Microbiol Lab, Cambridge, MA 02139 USA
关键词
D O I
10.1007/s002530051546
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The antibiotics have been useful in our battles against infectious bacteria and fungi for over 50 years. However, many antibiotics are used commercially, or are potentially useful, in medicine for activities other than their antibiotic action. They are used as antitumor agents, immunosuppressive agents, hypocholesterolemic agents, enzyme inhibitors, antimigraine agents, and antiparasitic agents. A number of these products were first discovered as antibiotics which failed in their development as such, or as mycotoxins. In addition to the above alternative applications, new powerful antibiotics have been discovered and commercialized in recent years and others are in clinical testing at the moment. A few successful secondary metabolites appear to have no antibiotic activity. The recently increased development of resistance to older antibacterial and antifungal drugs is being met with the use or clinical testing of older, underutilized or previously nondeveloped narrow-spectrum antibacterial products as well as powerful semisynthetic antifungal agents.
引用
收藏
页码:455 / 463
页数:9
相关论文
共 68 条
[1]   MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT [J].
ALBERTS, AW ;
CHEN, J ;
KURON, G ;
HUNT, V ;
HUFF, J ;
HOFFMAN, C ;
ROTHROCK, J ;
LOPEZ, M ;
JOSHUA, H ;
HARRIS, E ;
PATCHETT, A ;
MONAGHAN, R ;
CURRIE, S ;
STAPLEY, E ;
ALBERSSCHONBERG, G ;
HENSENS, O ;
HIRSHFIELD, J ;
HOOGSTEEN, K ;
LIESCH, J ;
SPRINGER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07) :3957-3961
[2]  
Barriere JC, 1998, CURR PHARM DESIGN, V4, P155
[3]  
Bentley R, 1997, PERSPECT BIOL MED, V40, P364
[4]  
BERDY J, 1995, P 9 INT S BIOL ACT 1, P3
[5]  
BIRNBAUM J, 1985, AM J MED, V78, P3, DOI 10.1016/0002-9343(85)90097-X
[6]   CEFOXITIN, A SEMISYNTHETIC CEPHAMYCIN - MICROBIOLOGICAL OVERVIEW [J].
BIRNBAUM, J ;
STAPLEY, EO ;
MILLER, AK ;
WALLICK, H ;
HENDLIN, D ;
WOODRUFF, HB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1978, 4 :15-32
[7]  
Black MT, 1998, CURR PHARM DESIGN, V4, P133
[8]   BIOLOGICAL EFFECTS OF CYCLOSPORIN-A - NEW ANTILYMPHOCYTIC AGENT [J].
BOREL, JF ;
FEURER, C ;
GUBLER, HU ;
STAHELIN, H .
AGENTS AND ACTIONS, 1976, 6 (04) :468-475
[9]   EMERGENCE OF DRUG-RESISTANT PNEUMOCOCCAL INFECTIONS IN THE UNITED-STATES [J].
BREIMAN, RF ;
BUTLER, JC ;
TENOVER, FC ;
ELLIOTT, JA ;
FACKLAM, RR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1831-1835
[10]   CRYSTAL AND MOLECULAR-STRUCTURE OF COMPACTIN, A NEW ANTIFUNGAL METABOLITE FROM PENICILLIUM-BREVICOMPACTUM [J].
BROWN, AG ;
SMALE, TC ;
KING, TJ ;
HASENKAMP, R ;
THOMPSON, RH .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1976, (11) :1165-1173